Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Avelumab in Pediatric Cancer Participants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 0 to less than 18 years of age at the time of first treatment dose with histologically or cytologically confirmed solid malignant tumors (including CNS tumors) or lymphoma for which no standard therapy is available~* Confirmed progression on or refractory to standard therapy or no standard therapy available.~* Availability of archival formalin-fixed, paraffin-embedded block containing tumor tissue, or slides, or a fresh/recent tumor biopsy prior to avelumab treatment for subjects in Phase 2~* Adequate bone marrow, kidney, and liver function~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Prior therapy with any antibody or drug targeting T-cell coregulatory proteins~* Concurrent anticancer treatment or immunosuppressive agents~* Prior organ transplantation~* Significant acute or chronic infections~* Other significant diseases or conditions that might impair the subject's tolerance of trial treatment~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Avelumab: 10 miligram per kilogram (mg/kg) (Type: EXPERIMENTAL): None
- Avelumab 20mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).